Key Facts Surrounding This News Item
- KPTI had a POWR Rating of D (Sell) coming into today.
- KPTI was -20.70% below its 10-Day Moving Average coming into today.
- KPTI was -26.91% below its 20-Day Moving Average coming into today.
- KPTI was -30.94% below its 50-Day Moving Average coming into today.
- KPTI was -31.23% below its 100-Day Moving Average coming into today.
- KPTI was -22.00% below its 200-Day Moving Average coming into today.
- KPTI had returned +29.53% year-to-date leading up to today’s news, versus a +5.65% return from the benchmark S&P 500 during the same period.
More Info About Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts. View our full KPTI ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!